Neuroprotection in Parkinson's disease: Love story or mission impossible?

Expert Review of Neurotherapeutics

Volumn 2, Issue 3, 2002, Pages 403-416

  Linazasoro, Gurutz J ^a  

^a HOSPITAL QUIRÓN   (Spain)

Author keywords

Apoptosis; Dopamine antagonists; Excitotoxicity; Mitochondria; Neuroprotection; Parkinson's disease; Pathogenesis; Protein aggregation; Selegiline; Ubiquitin proteasome system

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; LEVODOPA; NEUROTRANSMITTER; SELEGILINE;

DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; HUMAN; MENTAL DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; NOTE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS;

EID: 0036285744     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.3.403     Document Type: Note

References (97)

1. Chronic parkinsonism in humans due to a product of meperidine analog synthesis
2. Etiology and pathogenesis of Parkinson's disease
3. Is Parkinson's disease an inherited condition?
4. Alpha-synuclein and neurodegenerative diseases
5. Ubiquitination of a new form of a-syn by parkin from human brain: Implications for Parkinson's disease
6. Epidemiology of Parkinson's disease and akinetic syndromes
7. Chronic pesticide exposure reproduces features of Parkinson's disease
8. A new link between pesticides and Parkinson's disease
9. Familial aggregation of Parkinson's disease in Iceland
10. Late-onset neurodegenerative diseases-the role of protein insolubility
11. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
12. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases
13. Aggresomes, inclusion bodies and protein aggregation
14. Failure of the ubiquitin-proteasome system in Parkinson's disease
15. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders
16. Proteasomal function is impaired in substantia nigra in Parkinson's disease
17. Mitochondrial complex I deficiency in Parkinson's disease
18. Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions
19. A-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome
20. A one hit model of cell death in inherited neuronal degenerations
21. Enhanced vulnerability to oxidative stress by a-synuclein mutations and c-terminal truncation
22. Parkinson's disease in twins: An etiologic study
23. Complete genomic screen in PD: Evidence for multiple genes
24. Neurodegeneration: A failure of neuroregeneration?
25. Mitochondria and apoptosis
26. Apoptosis in neurodegenerative diseases: The role of mitochondria
27. Mechanisms of cell death in neurodegenerative disorders
28. Protective therapy for Parkinson's disease
29. Science, medicine and the future: Parkinson's disease
30. Ageing and Parkinson's disease: Substantia nigra regional selectivity
31. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with 18Fdopa PET
32. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins
33. Familial parkinsonism with synuclein pathology: Clinical and PET studies of A 30P mutation carriers
34. Abnormal performance on the PD test battery by asymptomatic first-degree relatives
35. Increased concentrations of a novel compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, in parkinsonian brains
36. Can the neuroprotective efficacy of an agent ever be conclusively proven?
37. The heterogeneity of Parkinson's disease: Clinical and prognostic implications
38. Assessing the integrity of the dopamine system in Parkinson's disease: How best to do it?
39. Novel observations with FDOPA-PET imaging after early nigrostriatal damage
40. Human positron emission tomographic 18Ffluorodopa studies correlate with dopamine cell counts and levels
41. 123IFP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease
42. Attempts to obtain neuroprotection in Parkinson's disease
43. The causes of Parkinson's disease are being unravelled and rational neuroprotective therapy is close to reality
44. The neurotoxicity of MPTP in the monkey and man
45. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-) deprenyl
46. Future of neuroprotection in Parkinson's disease
47. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease
48. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
49. Effect of lazabemide on the progression of disability in early Parkinson's disease
50. Selegiline and mortality in Parkinson's disease
51. Selegiline and Parkinson's disease. It's dèjá vu-again
52. Dopamine agonists and neuroprotection in Parkinson's disease
53. Apomorphine, a dopamine agonist with remarkable anti-oxidant and cytoprotective properties
54. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against MPTP apoptotic death in human neuroblastoma SH-SY 5Y cells
55. Neuroprotective effects of D 3 dopamine receptor agonists
56. Levodopa. Is toxicity a myth?
57. Levodopa neurotoxicity. Experimental studies versus clinical relevance
58. Chronic levodopa is not toxic for remaining dopamine neurons but instead promotes their recovery, in rats with moderate nigrostriatal lesions
59. Parkinson's disease, the effect of levodopa and the ELLDOPA trial
60. Mecanismos glutamatérgicos en la enfermedad de Parkinson
61. Alternative excitotoxic hypothesis
62. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energy metabolism impairment and NMDA receptor activation
63. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis
64. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
65. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease
66. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neurone degeneration after striatal 6-OHDA injection: Behavioural and immunohistochemical studies
67. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease
68. High frequency stimulation of the subthalamic nucleus increases extracellular contents of glutamate in substantia nigra and external pallidum
69. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease
70. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease
71. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: A pilot study
72. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for Parkinson's disease
73. Energetics in the pathogenesis of neurodegenerative diseases
74. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease
75. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys
76. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
77. Intraventricular administration of GDNF in the treatment of Parkinson's disease
78. Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets
79. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models
80. Parkinson's disease: Improved function with GM1 ganglioside treatment in a randomized placebo-controlled study
81. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
82. Neuropharmacologic aspects of apoptosis: Significance for neurodegenerative diseases
83. Caspases: Enemies within
84. Caspase inhibition reduces apoptosis and increases survival of nigral transplants
85. Multiple anti-oxidants in the prevention and treatment of neurodegenerative disease analysis of biologic rationale
86. Fullerene-based anti-oxidants and neurodegenerative disorders
87. Glia: A curtain raiser
88. The role of glial cells in Parkinson's disease
89. Experimental models of Parkinson's disease
90. A-Synuclein and the Lewy body disorders
91. Targetting small AB oligomers: The solution to an Alzheimer's disease conumdrum?
92. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced AB protofibril formation
93. Mutant protein in Huntington's disease is resistant to proteolysis in affected brain
94. Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
95. B-amyloid peptides enhance a-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
96. Pharmacological chaperones: A new twist on receptor folding